Joseph Moskal is a professor of biomedical engineering at the McCormick School of Engineering and Applied Science and a professor of neurological surgery at the Feinberg School of Medicine. As director of the Department of Biomedical Engineering’s Falk Center for Molecular Therapeutics, Moskal studies pharmacogenomics, drug discovery, and brain tumor therapeutics to develop novel technologies that help treat molecular biology-based diseases.

Moskal also founded and served as chief scientific officer of Naurex, Inc., a drug discovery company spun out of his research at Northwestern that develops therapies for difficult-to-treat depression and other central nervous system diseases. While at Naurex, his team developed rapastinel, a novel therapy for treatment-resistant major depression that is now in Phase III clinical trials. In 2015, Allergan acquired Naurex for $1.7 billion.

His past honors include the iCON Innovator Award from the Illinois Biotechnology Innovation Organization (iBIO), an industry association of more than 200 companies, academic institutions, and service providers dedicated to making Illinois and the Midwest a leader in life sciences ventures and technology. being named to the Chicago Area Entrepreneurship Hall of Fame, the American Institute for Medical and Biological Engineering’s (AIMBE) College of Fellows, and the National Academy of Inventors (NAI) 2017 Class of Fellows.

​BioPathways is a monthly event series, featuring prominent bioentrepreneurs, biotech executives and biotech investors in a fireside chat. We will also feature a guest biotech startup in a quick pitch. Parking is available for all attendees at Rosalind Franklin University.